Gene Vector Virus Core

项目摘要(GVVC) 作为斯坦福大学神经科学的三大核心之一，基因载体和病毒核心(GVVC)提供了病毒 在全脑、切片和细胞系统中操纵和表达重组蛋白的载体 一种在时间和空间上受控的方式。使用这些分子技术的能力对于 斯坦福大学相当数量的神经科学实验室的日常研究活动，以及随着 用于报告和操纵神经元功能以及追踪神经元的新分子工具的发展 更具特异性的联系，这些技术将仍然是推动我们在 了解大脑功能。在过去的4年里，GVVC制造了1348种病毒，并提供了219种预 为581个项目制作库存病毒。此外，GVVC还支持了创新的 光遗传学技术，其中光敏通道(通道视紫红质)被用来调节神经元 活动，由卡尔·戴瑟罗斯博士实验室发明。GVVC的后勤接近性及其对 戴瑟罗斯实验室不仅将这项技术传播给斯坦福大学的教职员工，还将其传播给其他许多人。 全国的神经学家。自成立以来，GVVC一直在不断增加 其病毒库(http://med.stanford.edu/gvvc/stockviruses.html)，可访问以供分发。在……下面 建议的拨款，GVVC将继续提供其目前的尖端服务。此外，GVVC将 开发新的服务，如CAV-2(犬腺病毒)病毒，将允许逆行轴突 交通。

Project Summary (GVVC) As one of three Stanford Neuroscience Cores, the Gene Vector and Virus Core (GVVC) provides viral vectors to manipulate and express recombinant proteins in the whole brain, in slices, and in cellular systems in a temporally and spatially controlled manner. The ability to employ these molecular techniques is essential to the daily research activities of a significant number of neuroscience labs at Stanford, and with the continued development of new molecular tools to report on and to manipulate neuronal function, and to trace neuronal connections with greater specificity, these techniques will remain critical to advancing our progress in understanding brain function. Over the past 4 years the GVVC has made 1348 viruses and provided 219 pre- made stock viruses for 581 projects. Moreover, GVVC has supported the viral production for the innovative optogenetics technology, in which light-sensitive channels (channelrhodopsins) are used to regulate neuronal activity, invented by the Dr. Karl Deisseroth laboratory. Logistical proximity of GVVC and its support for Deisseroth laboratory has led to dissemination of this technology not only to Stanford faculty but to many other neuroscientists nationwide. Since its inception, GVVC has continued to add to the number of stock viruses in its virus repository (http://med.stanford.edu/gvvc/stockviruses.html) which is accessible for distribution. Under the proposed grant, GVVC will continue to provide its present cutting-edge services. In addition, GVVC will develop new services, such as CAV-2 (canine adenovirus) virus, that will allow retrograde axonal transportation.